Skip to main content

Mirati Therapeutics Donates $4M to Stand Up to Cancer to Advance KRAS-Mutant Cancer Treatment

NEW YORK – Stand Up to Cancer (SU2C) and Mirati Therapeutics said on Monday that Mirati has awarded $4 million to SU2C to advance treatment for KRAS-mutant cancers.

SU2C, through its SU2C Catalyst program, will apply Mirati's grant toward research efforts to treat KRAS-mutant cancers with unmet need as well as tumor-agnostic strategies to treating KRAS-mutant cancers. The grant goes hand-in-hand with SU2C's plan to host a day-long innovation summit, during which experts in KRAS signaling, clinical trial design, tumor-agnostic approaches to cancer treatment, and others will collectively define a process by which researchers can apply for grants to advance KRAS-mutant cancer treatment.

The summit will also include discussions of ways to expand access to KRAS mutation testing across cancer types and diverse patient populations.

In keeping with the structure of SU2C's Catalyst program — through which companies donate funds to collaborative research studies and encourage the use of their products — Mirati's grant will go toward research projects specifically involving Mirati's investigational KRAS inhibitors, including its KRAS G12C inhibitor adagrasib.

"The opportunity to test the utility of KRAS inhibitors in several different cancer types is a great example of SU2C's cancer-agnostic approach to research," SU2C CEO Sung Poblete said in a statement.